AVBP Long Call Strategy

AVBP (ArriVent BioPharma, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

AVBP (ArriVent BioPharma, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $1.37B, a beta of 1.37 versus the broader market, a 52-week range of 17-35.83, average daily share volume of 533K, a public-listing history dating back to 2024, approximately 77 full-time employees. These structural characteristics shape how AVBP stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 1.37 indicates AVBP has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.

What is a long call on AVBP?

A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.

AVBP snapshot

As of August 14, 2026, spot at $29.66, ATM IV 112.50%, IV rank 17.72%, expected move 32.25%. The long call on AVBP below is built from the end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.

Why this long call structure on AVBP specifically: AVBP IV at 112.50% is on the cheap side of its 1-year range, which favors premium-buying structures like a AVBP long call, with a market-implied 1-standard-deviation move of approximately 32.25% (roughly $9.57 on the underlying). The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated AVBP expiries trade a higher absolute premium for lower per-day decay. Position sizing on AVBP should anchor to the underlying notional of $29.66 per share and to the trader's directional view on AVBP stock.

AVBP long call setup

The AVBP long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With AVBP at $29.66 on that close, the first option leg uses a $29.66 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed AVBP chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 AVBP shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Buy 1Call$29.66N/A

AVBP long call risk and reward

Net Premium / Debit
N/A
Max Profit (per contract)
Unbounded
Max Loss (per contract)
Unbounded
Breakeven(s)
None on modeled curve
Risk / Reward Ratio
N/A

Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.

AVBP long call payoff curve

Modeled P&L at expiration across a range of underlying prices for the long call on AVBP. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use long call on AVBP

Long calls on AVBP express a bullish thesis with defined risk; traders use them ahead of AVBP catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.

AVBP thesis for this long call

The market-implied 1-standard-deviation range for AVBP extends from approximately $20.09 on the downside to $39.23 on the upside. A AVBP long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current AVBP IV rank near 17.72% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on AVBP at 112.50%. As a Healthcare name, AVBP options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to AVBP-specific events.

AVBP long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. AVBP positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move AVBP alongside the broader basket even when AVBP-specific fundamentals are unchanged. Long-premium structures like a long call on AVBP are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current AVBP chain quotes before placing a trade.

Frequently asked questions

What is a long call on AVBP?
A long call on AVBP is the long call strategy applied to AVBP (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With AVBP stock at $29.66 on the most recent close, the strikes shown on this page are snapped to the nearest listed AVBP chain strike and the premiums come straight from that session's bid/ask midpoint.
How are AVBP long call max profit and max loss calculated?
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the AVBP long call priced from the end-of-day chain at a 30-day expiry (ATM IV 112.50%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a AVBP long call?
The breakeven for the AVBP long call priced on this page is no defined breakeven on the modeled curve at expiration, derived from the end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The AVBP market-implied 1-standard-deviation expected move in the same options snapshot is approximately 32.25%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a long call on AVBP?
Long calls on AVBP express a bullish thesis with defined risk; traders use them ahead of AVBP catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
How does current AVBP implied volatility affect this long call?
AVBP ATM IV is at 112.50% with IV rank near 17.72%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

Related AVBP analysis